Leonard Post Sells 5,000 Shares of CG Oncology (NASDAQ:CGON) Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total transaction of $350,000.00. Following the completion of the transaction, the director owned 5,000 shares in the company, valued at $350,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

CG Oncology Stock Down 1.2%

CGON opened at $71.96 on Friday. CG Oncology, Inc. has a twelve month low of $23.65 and a twelve month high of $75.50. The company has a fifty day moving average of $64.40 and a 200-day moving average of $58.00. The stock has a market cap of $6.35 billion, a PE ratio of -30.88 and a beta of 0.31.

CG Oncology (NASDAQ:CGON) last announced its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The company had revenue of $1.08 million for the quarter, compared to analyst estimates of $0.45 million. Sell-side analysts anticipate that CG Oncology, Inc. will post -2.89 EPS for the current fiscal year.

Institutional Trading of CG Oncology

Several large investors have recently made changes to their positions in CGON. JPMorgan Chase & Co. raised its stake in CG Oncology by 321.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 227,879 shares of the company’s stock worth $9,179,000 after buying an additional 173,785 shares during the period. Vanguard Group Inc. grew its stake in CG Oncology by 11.4% in the third quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock valued at $264,933,000 after acquiring an additional 670,770 shares during the period. Mangrove Partners IM LLC grew its stake in CG Oncology by 21.0% in the third quarter. Mangrove Partners IM LLC now owns 671,692 shares of the company’s stock valued at $27,056,000 after acquiring an additional 116,575 shares during the period. Sivik Global Healthcare LLC bought a new stake in shares of CG Oncology during the fourth quarter valued at approximately $1,453,000. Finally, HighVista Strategies LLC increased its holdings in shares of CG Oncology by 152.1% during the third quarter. HighVista Strategies LLC now owns 26,040 shares of the company’s stock valued at $1,049,000 after acquiring an additional 15,712 shares in the last quarter. 26.56% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on CGON shares. Wedbush upped their target price on CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. JPMorgan Chase & Co. boosted their price target on CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a report on Monday, April 20th. Wall Street Zen downgraded shares of CG Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Finally, Wolfe Research started coverage on shares of CG Oncology in a research report on Tuesday, May 19th. They set a “peer perform” rating for the company. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $81.73.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.